Treatment of pyoderma gangrenosum with cyclosporine

Matis, W. L.

doi:10.1001/archderm.128.8.1060

Cited by 34 publications

(23 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Systemic therapy is based on oral steroids at doses of 0.5–2 mg/kg/day. If not successful, methylprednisolone 1 mg/kg in continuous infusion for 1–5 consecutive days [4, 6, 7] or cyclosporine in a dosage of 4–5 mg/kg/day has been associated with rapid responses [8,9,10,11,12]. Azathioprine [4, 58, 59], methotrexate [60], tacrolimus [61,62,63,64], thalidomide [65], dapsone [66, 67], mycophenolate mofetil [68], cyclophosphamide [69] and colchicine [70] have shown some effectiveness in case reports.…”

Section: Discussionmentioning

confidence: 99%

“…Topical anti-inflammatory medication should only be used in combination with systemic treatments such as oral or intravenous corticosteroids [4, 6, 7]. Cyclosporine, mycophenolate mofetil, dapsone and other immunosuppressive agents have been used successfully as steroid-sparing drugs [8,9,10,11,12]. Some of these agents are however associated with potentially severe long-term adverse events.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Infliximab for the Treatment of Disseminated Pyoderma Gangrenosum Associated with Ulcerative Colitis

Juillerat¹,

Christen-Zäch

Troillet³

et al. 2007

Dermatology

View full text Add to dashboard Cite

We report the case of a 19-year-old woman who developed an acute disseminated pyoderma gangrenosum (PG) during a severe flare of ulcerative colitis (UC). She was successfully treated with a 3-dose regimen of the anti-tumor-necrosis-factor-α antibody infliximab. The literature on the effectiveness of this biological agent was reviewed, including 8 other cases of UC-associated PG and 77 cases of Crohn’s-disease-associated PG. This case report and the review of the literature demonstrate that infliximab can be successfully used to treat patients with PG associated with inflammatory bowel diseases.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Infliximab for the Treatment of Disseminated Pyoderma Gangrenosum Associated with Ulcerative Colitis

Juillerat¹,

Christen-Zäch

Troillet³

et al. 2007

Dermatology

View full text Add to dashboard Cite

show abstract

“…After low-dose cyclosporine, 10 of 11 patients cleared rapidly and completely their PG [52]. In a retrospective analysis of 11 steroid-refractory IBD-associated (5 UC, 6 CD) PG cases, a closure of the PG within 4–5 days, independently of intestinal disease activity, was observed with cyclosporine.…”

Section: Treatmentmentioning

confidence: 99%

Extraintestinal Manifestations of Crohn’s Disease

et al. 2005

View full text Add to dashboard Cite

In each case of extraintestinal manifestations of Crohn’s disease, active disease, if present, should be treated to induce remission, which may positively influence the course of most concomitant extraintestinal manifestations. For some extraintestinal manifestations, however, a specific treatment should be introduced. This latter part of disease management will be discussed in this chapter, in particular for pyoderma gangrenosum, uveitis, spondylarthropathy – axial arthropathy – and primarysclerosing cholangitis, which have also been described in quiescent Crohn’s disease. Few new drugs for the treatment of extraintestinal manifestations of Crohn’s disease have been developed in the past and only the role of infliximab has increased in Crohn’s disease-related extraintestinal manifestations. Drugs specifically aimed at this treatment, stemming from a few randomized controlled studies or case series, are sulfasalazine, 5-ASA, corticosteroids, azathioprine or 6-mercaptopurine, methotrexate, infliximab, dapsone and cyclosporine or tacrolimus.

show abstract

“…Since the early 90s, systemic ciclosporine has been considered to be the ‘first-line’ treatment [3]. Many reports have claimed its unrivalled efficacy [4, 5, 6, 7, 8, 9]that permits to obtain in most cases complete healing of the lesions, without additional therapy.…”

Section: Discussionmentioning

confidence: 99%

“…Blood pressure was normal (13/8). It was therefore decided to treat the patient with oral ciclosporine, already advocated at that time as the first-line therapy [3]. It is emphasized that the patient was treated with the ‘old’ formulation of ciclosporine (Sandimmun ® solution).…”

Section: Case Reportmentioning

confidence: 99%

Superficial Granulomatous Pyoderma gangrenosum of the Face, Successfully Treated by Ciclosporine: A Long-Term Follow-Up

Lachapelle

Jabłońska²

2001

Dermatology

View full text Add to dashboard Cite

We report a case of the superficial granulomatous (vegetating) form of pyoderma gangrenosum, involving the forehead and the left temporal area in a 44-year-old woman. No association with other pathologies could be found. Lesions responded dramatically to systemic ciclosporine (5 mg/kg/day), and complete healing was reached after 6 months. Doses were tapered progressively. Treatment was discontinued after 4.5 years. Discontinuation was not followed by recurrence of the disease. Healing is maintained after another 4.5 years of follow-up.

show abstract

Treatment of pyoderma gangrenosum with cyclosporine

Cited by 34 publications

References 0 publications

Infliximab for the Treatment of Disseminated Pyoderma Gangrenosum Associated with Ulcerative Colitis

Infliximab for the Treatment of Disseminated Pyoderma Gangrenosum Associated with Ulcerative Colitis

Extraintestinal Manifestations of Crohn’s Disease

Superficial Granulomatous Pyoderma gangrenosum of the Face, Successfully Treated by Ciclosporine: A Long-Term Follow-Up

Contact Info

Product

Resources

About